Supernus Pharmaceuticals (NASDAQ: SUPN) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Supernus Pharmaceuticals to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Insider & Institutional Ownership

95.4% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 6.7% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Supernus Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Supernus Pharmaceuticals $252.59 million $82.36 million 21.18
Supernus Pharmaceuticals Competitors $2.40 billion $905.93 million 0.16

Supernus Pharmaceuticals’ competitors have higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Supernus Pharmaceuticals has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals’ competitors have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.


This table compares Supernus Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals 41.10% 30.73% 19.48%
Supernus Pharmaceuticals Competitors -540.60% -41.61% -24.68%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Supernus Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals 0 3 3 0 2.50
Supernus Pharmaceuticals Competitors 63 300 947 27 2.70

Supernus Pharmaceuticals presently has a consensus target price of $47.50, suggesting a potential upside of 15.01%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 18.76%. Given Supernus Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Supernus Pharmaceuticals has less favorable growth aspects than its competitors.


Supernus Pharmaceuticals competitors beat Supernus Pharmaceuticals on 7 of the 13 factors compared.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.